SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Rituximab is used as a standard of care for follicular lymphoma and is usually administered intravenously. A novel subcutaneous formulation recently showed non-inferior efficacy with similar pharmacokinetic and safety profiles compared to intravenous rituximab in patients with follicular lymphoma. This new approach is promising in terms of comfort for patients and time-saving for hospital staff. To evaluate the real-life economic impact of subcutaneous rituximab as maintenance therapy in patients with follicular lymphoma in real life, we conducted a cost-consequence analysis from the hospital's point of view in three French teaching hospitals. Health-related quality of life (EQ-5D-3L) was investigated as well as patients' and nurses' perception. Compared to intravenous rituximab, subcutaneous administration showed an estimated cost-saving of €109.20 per patient per cycle (p < 0.001), 78.6% of which could be attributed to the rituximab cost. Health-related quality of life showed no significant difference between the two groups despite tendencies for greater pain in the subcutaneous group and greater anxiety in the intravenous group. Thus, subcutaneous rituximab had a favorable pharmacoeconomic profile, with clinical efficacy similar to that of intravenous rituximab. The subcutaneous form was preferred by almost all patients, but further consideration should be given to improve the patients' experience: a dedicated day unit with trained medical, nursing, and pharmaceutical staff could be helpful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Differences in HCP time per infusion of rituximab were reported in five publications and directly measured [88, 90–92, 104].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [91]
Citations
Cites
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Self-citationSant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadié, M., Simonetti, A., Lutz, J.-M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282632 · Cited by 977
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Self-citationVidal, L., Gafter-Gvili, A., Leibovici, L., Dreyling, M., Ghielmini, M., Hsu Schmitz, S.-F., Cohen, A., & Shpilberg, O. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn478 · Cited by 266
Tan, D. C. L., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., Warnke, R. A., Natkunam, Y., Han, S. S., Yuen, A. R., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491514 · Cited by 262
Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Vitolo, U., & Ladetto, M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw400 · Cited by 216
Self-citationValuing EQ-5D using Time Trade-Off in France
Chevalier, J., & de Pouvourville, G. (2013) · The European Journal of Health Economics · doi:10.1007/s10198-011-0351-x · Cited by 199
Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154 · cited 3×
“Time-saving was the main reason for preferring the SC formulation, findings also observed in PrefMab [21].”
MethodResultInfluentialVidal, L., Gafter‐Gvili, A., Salles, G. A., Dreyling, M. H., Ghielmini, M. E. G., Schmitz, S. H., Pettengell, R., Witzens‐Harig, M., & Shpilberg, O. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr418 · Cited by 143
Self-citationSubcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138 · cited 1×
“Recombinant human hyaluronidase was developed to solve this problem (by degrading temporarily the SC matrix), allowing SC delivery of larger molecules such as antibodies that might not otherwise be feasible [9].”
BackgroundDavies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114 · cited 1×
“The randomized phase III SABRINA study, performed on 127 patients, demonstrated non-inferior pharmacokinetics parameters for SC compared to IV rituximab in patients with previously untreated follicular lymphoma, during induction therapy [11, 12].”
MethodSalles, G., Seymour, J. F., Feugier, P., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.509.509 · Cited by 83
Self-citationRule, S., Collins, G. P., & Samanta, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914033 · Cited by 66 · cited 1×
“in the UK showed that SC rituximab was associated with reduced active healthcare professional (HCP) time (defined as the time dedicated to a specific task involving physical presence) and costs compared to IV rituximab [13].”
BackgroundCost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma
Deconinck, É., Miadi-Fargier, H., Pen, C. L., & Brice, P. (2009) · PharmacoEconomics · doi:10.2165/11314070-000000000-00000 · Cited by 49
Leizorovicz, A., Becker, F., Buchmuller, A., Quéré, I., Prandoni, P., & Decousus, H. (2013) · Blood · doi:10.1182/blood-2013-04-498014 · Cited by 48
Olofsson, S., Norrlid, H., Karlsson, E., Wilking, U., & Ragnarson Tennvall, G. (2016) · The Breast · doi:10.1016/j.breast.2016.07.008 · Cited by 45 · cited 1×
“A similar comparison between IV and SC trastuzumab showed equivalent results, findings a medical cost reduction of €101 (drug, materials, and nurse time), and a majority of patients preferring SC over IV administration [26].”
ResultThe impact of biosimilars' entry in the EU market
Rovira, J., Espín, J., García, L., & Lima, A. O. D. L. (2014) · Cited by 40
Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
Cesarec, A., & Likić, R. (2016) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0285-7 · Cited by 35
SIE , SIES , GITMO revised guidelines for the management of follicular lymphoma
Zinzani, P. L., Marchetti, M., Billio, A., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23372 · Cited by 34
Witzens‐Harig, M., Reiz, M., Heiß, C., Benner, A., Hensel, M., Neben, K., Dreger, P., Kraemer, A., & Ho, A. D. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0560-2 · Cited by 28
Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion
Mihajlović, J., Bax, P., van Breugel, E., Blommestein, H. M., Hoogendoorn, M., Hospes, W., & Postma, M. J. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.342 · Cited by 25
Herceptin® (trastuzumab) par voie sous-cutanée : une mini révolution ? Étude pharmaco-économique
Lieutenant, V., Toulza, É., Pommier, M., & Lortal-Canguilhem, B. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.01.007 · Cited by 15
�valuation de la qualit� de vie en oncologie: I?D�finitions et objectifs
Br�dart, A., & Dolbeault, S. (2005) · Psycho-Oncologie · doi:10.1007/s10332-005-0047-5 · Cited by 13
De Cock, E., Kritikou, P., Tao, S., Wiesner, C., Waterboer, T., & Carella, A. M. (2013) · Blood · doi:10.1182/blood.v122.21.1724.1724 · Cited by 7
Cited by
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology · doi:10.2217/fon-2019-0368 · Cited by 69
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
“In the European publications, non-drugrelated cost savings included savings related to HCP time [53, 91, 92, 103], consumables [53, 91], and day-care unit costs [53, 95].”
BackgroundAguiar-Ibáñez, R., Fotheringham, I., Mittal, L., Sillah, A., & Pathak, S. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02985-9 · Cited by 19
“Only one observational study reported HRQoL/utilities data [33, 48].”
Influential
Metadata
- Authors
- Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., Tomaré, P., Tournamille, J.-F., Schwiertz, V., Vantard, N., Le Gouill, S., Gyan, E., Salles, G., & Rioufol, C.
- Affiliations
- Lyon 1 Université (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Université de Tours (FR)
- Corresponding author
- Rioufol, Catherine
- ORCID
- Venue
- Annals of Hematology
- Published
- 2017-10-10
- Volume
- 97
- Issue
- 1
- Pages
- 123-131
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- OpenAlex
- W2761412232
- Cited by
- 20
- References
- 24
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Hematology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- follicular lymphoma, maintenance therapy, cost-consequence analysis, pharmacoeconomics, health-related quality of life, patient preferences, nurses' perceptions, hospital cost savings, monoclonal antibodies
- MeSH terms
- Rituximab, Adult, Aged, Aged, 80 and over, Cost-Benefit Analysis, Cross-Sectional Studies, Female, France, Hospitals, Teaching, Humans, Injections, Subcutaneous, Lymphoma, Follicular, Male, Middle Aged, Quality of Life, Drug Costs, Patient Preference, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.